Call our Clinical Research Coordinator at 502-589-1500 to find out if participation in any of our studies for Dry Eye Disease, Cataract, Ocular, Allergies, LASIK laser vision correction, Glaucoma, Presbyopia, or Conjunctivitis may be right for you.
We regularly recruit patients (study subjects) to enroll in trials sponsored by pharmaceutical companies, surgical and medical equipment firms, and others attempting to prove the usefulness of a new pharmaceutical agents, treatments, surgical implants or diagnostic medical devices.
All of these clinical studies are done with the ultimate goal of getting the medication, treatment, implant or device to become approved by the United States Food & Drug Administration (FDA).
At The Eye Care Institute, we take your health, wellness and vision very seriously. That’s why we only participate in Phase II, III and IV trials, along with post-marketing studies. Specifically, after the treatment, device, implant or drug has been proven not to be harmful, we then participate in clinical trials to determine how successfully the item being tested works, and for how long.
If you want to be included in a clinical study, please use this form to be considered for treatment of these conditions:
- Dry Eye Disease
- Ocular (eye) allergies
- LASIK laser vision correction
Participation in clinical trials offers patients access to new medications, diagnostic treatments or surgical implants (all at no cost) which may improve the quality of your vision or improve your comfort. Further, your participation may have a positive impact of the lives of patients in the future. Many studies offer compensation for your travel expense and time.
Here is a listing of many of the significant clinical trials in which we have participated (scroll the list to view all):
|Glaucoma/Ocular Hypertension (Japanese/Japanese-American Population)||A prospective, double-masked, randomized, multicenter, placebo-controlled, parallel-group study assessing the safety and efficacy and optimum concentration to be used clinically of investigational product in Japanese/Japanese American subjects with open angle glaucoma or ocular hypertension.||Enrolling Summer 2018|
|Glaucoma/Ocular Hypertension||A randomized, double-masked, active-controlled, parallel group, multi-center bioequivalence study of a generic 1% ophthalmic suspension compared to reference listed drug ophthalmic suspension 1% in subjects with primary open angle glaucoma or ocular hypertension.||April 2018- Present|
|Cataract Surgery||A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of a generic 0.3% ophthalmic suspension compared to the name brand ophthalmic suspension 0.3% for the treatment of pain and inflammation associated with cataract surgery.||March 2018- Present|
|Glaucoma/Ocular Hypertension||A comparison of investigational product to selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension.||March 2018- Present|
|Chalazion||A multi-center, double-masked, randomized, placebo-controlled evaluation of the safety and efficacy of an investigational product transdermal system (TDS) as compared to placebo TDS in patients with a chalazion.||July 2017- Present|
|Sjögren’s Syndrome||A double-masked, randomized, multi-center phase 2 study to evaluate the efficacy and safety of investigational ophthalmic solution in subjects with dry eye associated with primary Sjögren’s syndrome.||July 2017- Present|
|Neurotrophic Keratopathy||A phase 3, multi-center, randomized, double-masked, placebo-controlled clinical Study to Assess the safety and efficiency of an investigational ophthalmic solution for the treatment of neurotrophic keratopathy.||May 2017- Present|
|Adenoviral Conjunctivitis||A phase 3, multi-center, randomized, double-masked study to evaluate the clinical efficacy and safety of investigational ophthalmic suspension compared to placebo in the treatment of adenoviral conjunctivitis.||May 2017- Present|
|Bacterial Conjunctivitis||A phase 3, multi-center, randomized, double-masked study to evaluate the clinical efficacy and safety of investigational ophthalmic suspension compared to placebo in the treatment of bacterial conjunctivitis.||May 2017- Present|
|Presbyopia||A prospective, multi-center clinical trial of an investigational implant system for improvement of near visual acuity in presbyopic patients.||November 2014- Present|
Past Clinical Trials
|Dry Eye Disease||A multi-center, randomized, controlled, double-masked clinical trial to evaluate the efficacy of investigational nasal spray on signs and symptoms of dry eye disease.||March 2018 - April 2018|
|Dry Eye Disease||A Phase 2b/3, multi-center, randomized, double-masked, vehicle-controlled clinical study to assess the efficacy and safety of topical ocular solution for the treatment of signs and symptoms of dry eye disease.||November 2017- February 2018|
|Dry Eye Disease||A multi-center, randomized, double-masked, placebo controlled clinical study to assess the safety and efficacy of investigational ophthalmic solution for the treatment of dry eye in a controlled adverse environment.||January 2017- March 2017|
|Presbyopia||A phase 2, multicenter, double-masked, randomized, vehicle-controlled, parallel-group study evaluating the safety, efficacy and pharmacokinetics of a fixed combination of investigational products (ophthalmic solution) in patients with presbyopia.||June 2016- August 2017|
|Dry Eye Disease||A phase 3, double-masked, randomized, controlled study of investigational ophthalmic suspension compared to vehicle in subjects with dry eye disease.||July 2016- September 2017|
|Corneal Wound||A double-masked, randomized, multicenter, placebo-controlled parallel-group study of investigational ophthalmic solution compared with placebo to assess safety and efficacy of two dose concentrations for corneal epithelial wound healing in subjects with moderated to severe corneal epithelial disorders.||October 2016- April 2017|
|Glaucoma||A phase 1-2 multi-center, randomized, controlled, dosing-finding study designed to evaluate the safety and ocular hypotensive efficacy of 3 dose levels of the investigational sustained release subconjunctival insert in subjects with open-angle glaucoma or ocular hypertension.||September 2016- April 2017|
|Dry Eye Disease||Multi-center, randomized, controlled, single-masked, cross-over clinical trial to evaluate the reduction in the exacerbation of dry eye symptoms upon exposure to a controlled adverse environment with treatment by an investigational device.||September 2016- November 2016|
|Cataract Surgery||A phase 3, double-masked, randomized, controlled study to evaluate the safety and efficacy of investigational ophthalmic suspension in subjects with postsurgical inflammation and pain.||June 2016- April 2017|
|Dry Eye Disease||A safety and efficacy study of investigational ophthalmic solutions for the treatment of dry eye disease.||January 2016- September 2016|
|Glaucoma/ Ocular Hypertension||A phase 3 prospective, double-masked, randomized, multi-center, active-controlled, parallel group, 12-month study assessing the safety and ocular hypotensive efficacy of investigative ophthalmic solution compared other ophthalmic solution, 0.02%, and another ophthalmic solution, 0.005% in subjects with elevated intraocular pressure.||September 2015- July 2017|
|Dry Eye Disease||A phase 3 multi-center, double-masked, randomized, controlled, efficacy and safety study of investigational topical ophthalmic solution versus vehicle control in subjects with moderated to severe dry eye disease.||March 2014- November 2015|
|Glaucoma and Cataract||Safety and effectiveness of an investigational aqueous implant for lowering intraocular pressure in glaucoma patients undergoing cataract surgery, a prospective, multicenter, randomized, controlled clinical trial.||February 2014- Present|
|Cataract Surgery||Multi-Center, Double Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) versus Vehicle Gel for the treatment of Ocular Inflammation and Pain Following Cataract Surgery, sponsored by Bausch & Lomb||February 2014 to August 2014|
|Dry Eye||A Randomized, Multi-Center, Parallel-Group Safety and Efficacy Study of Lotemax Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects with Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED), sponsored by Bausch & Lomb, Inc.||May 2013 to June 2014|
|Dry Eye||Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Currently Using Artificial Tears (OPUS-2), sponsored by Shire,||December 2012 to October 2013|
|Dry Eye||A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease, sponsored by Bausch & Lomb, Inc.||December 2012 to December 2011|
|Cataract Surgery||Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery, sponsored by Bausch & Lomb, Inc.||May 2011 to December 2011|
|Dry Eye||Efficacy and Safety Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination TID vs. Brinzolamide 1% TID and Brimonidine 0.2% TID, sponsored by Alcon Research.||March 2011 to March 2012|
|Cataract Surgery||Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery, sponsored by Bausch & Lomb, Inc.||June 2008 to November 2008|
|Dry Eye||Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007), sponsored by Sirion Therapeutics, Inc.||October 22, 2007 to June 29, 2011|
|Glaucoma||A Study of Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients with Open-Angle Glaucoma, sponsored by Alcon Research.||March 2007 to July 2009|
|Glaucoma||Dorzolamide-Timolol as First Line Therapy to Reduce Intraocular Pressure in Patients With Untreated Open Angle Glaucoma (OAG) or Ocular Hypertension (OH), sponsored by Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.||May 2006 to August 2007|
|Cataract Surgery||A Study of the Glaukos Trabecular Micro-Bypass Stent in Combination With Cataract Surgery in Open Angle Glaucoma Subjects, sponsored by Glaukos Corporation.||June 2005 to March 2010|
|Presbyopia||A Prospective, Multicenter Clinical Trial of the PresVIEW Scleral Implant (PSI) For the Improvement of near Visual Acuity in Presbyopic Patients, sponsored by Refocus Group, Inc.||December 2003 to March 2015|
|Cataract Surgery||Efficacy and Safety of Topical Bromfenac Ophthalmic Solution, 0.09% vs. Placebo for Treatment of Ocular Inflammation Following Cataract Surgery, sponsored by Bausch & Lomb, Inc.||May 2003 to January 2004|
|Corneal Erosion||Topical Dehydrex in Treating Recurrent Corneal Erosion, sponsored by FDA Office of Orphan Products Development.||September 2001 to August 2004|
|Aqueous Dynamics||Effects of AGN 192024 on Aqueous Dynamics, sponsored by Allergan, Inc.||January 2001|
|Glaucoma||A 6-Month, Randomized, Double-Masked Comparison Of Fixed Combination Of Latanoprost And Timolol With The Individual Components, Continuing Into A 6-Month Open Label Safety Study Of Fixed Combination In Patients With Glaucoma Or Ocular Hypertension, sponsored by Pfizer, Inc.||August 1997 to June 1999|
Other Clinical Trial Involvement
|Ophthalmic Exams||Multiple Contracts for Ophthalmic Exams to Be Coordinated as Needed with Clinical Trials Being Conducted at Norton Healthcare. Sponsored by Norton Cancer Institute.||2014-Present|
Study sponsors, pharmaceutical companies, biotechnology firms and CRO’s: If you wish to consider using our site, please contact us at email@example.com.
The Eye Care Institute is a member of the Society for Clinical Research Sites.